Donal McLornan

Feb 20, 2024 | nature.com | Dietrich Wilhelm Beelen |Friedrich Stölzel |Fabio Ciceri |Wolfgang Andreas Bethge |Peter Dreger |Donal McLornan | +2 more

AbstractA randomized study (acronym: MC-FludT.14/L Trial II) demonstrated that fludarabine plus treosulfan (30 g/m²) was an effective and well tolerated conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

May 9, 2023 | nature.com | Meral Beksac |Patrice Chevallier |John A Snowden |Monika Engelhardt |Donal McLornan |Patrick J. Hayden | +1 more

AbstractEarly relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m2 (Mel200) (n = 7228; 2014–2017) (training cohort); Mel200 (n = 5616; 2018–2019) or Mel140 (n = 1523; 2018–2019) (validation cohorts).

Mar 28, 2023 | nature.com | Olivier Tournilhac |Peter Dreger |Vladan Vucinic |Pavel Jindra |Patrice Chevallier |Edouard Forcade | +6 more

AbstractAllogeneic transplantation (allo-HCT) is a curative treatment in CLL whose efficacy including the most severe forms had led to the 2006 EBMT recommendations. The advent after 2014 of targeted therapies has revolutionized CLL management, allowing prolonged control to patients who have failed immunochemotherapy and/or have TP53 alterations. We analysed the pre COVID pandemic 2009–2019 EBMT registry.